Olumiant (baricitinib) is a prescription medication used to treat rheumatoid arthritis in adults. It is an oral medication that is available in tablet form.

Uses:

Olumiant is used to treat moderately to severely active rheumatoid arthritis in adults who have not responded well to other medications, such as methotrexate.

HOW TO USE:

Olumiant is taken orally with or without food. The tablet should be swallowed whole and not crushed, broken, or chewed. The dosage and duration of treatment should be determined by the healthcare provider.

Dosage:

The recommended dose of Olumiant is 2mg once daily. If a patient is also taking CYP3A4 inhibitors, such as ketoconazole, the dosage may be reduced.

Mechanism of Action:

Olumiant works by inhibiting the activity of enzymes called Janus kinase (JAK) 1 and 2. These enzymes are involved in the process of inflammation, which is the underlying cause of rheumatoid arthritis. By inhibiting these enzymes, Olumiant helps reduce inflammation and relieve the symptoms of rheumatoid arthritis.

Storage Conditions:

Olumiant should be stored at room temperature between 20°C and 25°C.

Precautions:

• Olumiant may increase the risk of serious infections, such as tuberculosis and herpes zoster. Patients should be evaluated for these infections before starting treatment and monitored during treatment.
• Patients should inform their healthcare provider of any signs or symptoms of an infection while taking Olumiant.
• Olumiant may increase the risk of blood clots, so patients with a history of blood clots should not take this medication.
• Patients should not receive live vaccines while taking Olumiant.

Interactions:

• Olumiant may interact with other medications, including CYP3A4 inhibitors and immunosuppressants. Patients should inform their healthcare provider of all medications they are taking before starting treatment with Olumiant.

Contraindications:

• Olumiant is contraindicated in patients who have a hypersensitivity to baricitinib or any of its components.
• It should not be used in combination with other JAK inhibitors.

Side Effects:

The most commonly reported side effects of Olumiant include upper respiratory tract infections, nausea, herpes zoster infection, and increased levels of cholesterol and liver enzymes. Serious adverse events reported include blood clots, infections, and malignancies. Patients should inform their healthcare provider of any unusual symptoms while taking Olumiant.

Overdose:

No cases of overdose have been reported with Olumiant.

In conclusion, Olumiant (baricitinib) is an oral medication used to treat moderately to severely active rheumatoid arthritis in adults. The recommended dosage is 2mg once daily, and it works by inhibiting JAK enzymes, which are involved in inflammation. Olumiant is stored at room temperature and is contraindicated in patients who have a hypersensitivity to baricitinib or any of its components. Patients should be evaluated for infections before and during treatment, and they should not receive live vaccines. The most common side effects of Olumiant include upper respiratory tract infections, nausea, and herpes zoster infection. Serious adverse events reported include blood clots, infections, and malignancies. There are no reported cases of overdose associated with Olumiant.